Albireo Reports Second Quarter 2019 Financial Results
— Odevixibat Phase 3 PEDFIC 1 topline results expected mid-2020 — — Initiated elobixibat Phase 2 trial in NAFLD/NASH — — Management to host conference call and webcast today at 10 a.m. EDT — BOSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. ( …